PD173074

PD173074 is an inhibitor of FGFR1 and VEGFR2 used in studies of MAPK / ERK Signaling and Apoptosis. It is especially relevant in angiogenesis, apoptosis, and cancer models, where defined compound exposure can be linked to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions.

By inhibiting FGFR1 and VEGFR2, PD173074 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and caspase-associated cell-death signaling and survival decisions. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In angiogenesis, apoptosis, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving FGFR1 and VEGFR2
• Pathway perturbation studies connected to MAPK / ERK Signaling and Apoptosis
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, PD173074 is appropriate when a defined chemical perturbant is needed to connect FGFR1 and VEGFR2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in angiogenesis, apoptosis, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.